E-cigarette or vaping product use associated lung injury (EVALI) in the time of COVID-19: A clinical dilemma.
Daniel HelfgottGabrielle CapozzoliJovanna MadrayAisha BaigLakshmi UppaluriSunanda GaurMitchell SimonJudith AmorosaMaya RamagopalPublished in: Pediatric pulmonology (2022)
Clinical and radiological features are similar in both EVALI and SARS-CoV-2 infection. Inflammatory markers are elevated in both conditions. A detailed social and substance use history in patients presenting with "typical" COVID pneumonia like illness is important. EVALI should be ruled in early to start the appropriate treatment. Given the ongoing pandemic, pediatricians and other health-care providers need to be aware of other conditions that can masquerade as SARS-CoV-2.